Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

Coverage, in order

1. 1d ago
   
   Guardian Science UK mainstream study

   Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn

   GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention away from diabetes treatments such as insulin, the head of the Access to Medicine…

Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.